No doctors at Mission Memorial Hospital ER Sunday night
Due to a lack of available physicians, there will be a 'temporary service interruption' in the emergency department at Mission Memorial Hospital in B.C.'s Lower Mainland Sunday night.
Anyone who arrives in the emergency room after 5 p.m. will not be seen by a doctor, Fraser Health said in a memo sent at 1 p.m. Those who arrive before that time will be seen by a physician before they end their shift at 11 p.m.
After that, there will be no doctors in the ER but nurses will be on-staff to 'support walk-in patients needing basic care, assist with re-direction of care, and/or transfer patients with urgent needs to a neighbouring hospital.'
Fraser Health asked anyone experiencing a life-threatening emergency to call 911 for transport to the 'nearest available and appropriate facility.'
The 'service interruption' is scheduled to last until 8 a.m. Monday.
'All other Fraser Health Emergency Departments remain open and have emergency physicians on site; however, high numbers of people seeking care and human resources challenges at many of our hospital emergency departments may lead to longer wait times for patients with non-urgent care concerns,' the health authority wrote.
Mission Memorial Hospital's ER has diverted patients at least three times this year. While ER closures are a common occurrence in B.C.'s smaller communities, staffing issues have begun periodically disrupting service at Vancouver-area hospitals in recent years.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
26 minutes ago
- Globe and Mail
Pyoderma Gangrenosum Market Set for Expansion with Orphan Drug Designations and Pipeline Acceleration
The pyoderma gangrenosum treatment market is experiencing significant expansion, driven by increasing disease awareness, rising healthcare spending, and breakthrough therapies from key pharmaceutical players, including Johnson & Johnson, AbbVie, Amgen, Novartis, Eli Lilly and Company, Genentech, Galderma, Bristol Myers Squibb, Pfizer, LEO Pharma, and others. DelveInsight's " Pyoderma Gangrenosum Market Insight, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the pyoderma gangrenosum treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and pyoderma gangrenosum market forecasts through 2032, providing crucial insights for stakeholders in this specialized therapeutic area. According to DelveInsight's analysis, the pyoderma gangrenosum treatment market is projected to grow substantially with a notable CAGR during the forecast period (2023-2032), driven by enhanced understanding of disease mechanisms, improved diagnostic capabilities, and novel therapeutic approaches targeting the underlying immune system dysfunction. Download the Pyoderma Gangrenosum Market report to understand which factors are driving the therapeutic market @ Pyoderma Gangrenosum Market Trends. The epidemiological analysis reveals that pyoderma gangrenosum affects approximately 1 in 100,000 Americans, with women being somewhat more frequently affected than men. The condition most frequently occurs between the ages of 20 and 50, while less than 4 percent of incidents involve infants or teenagers. Furthermore, significant regional variations exist across the seven major markets, with the United States representing a substantial portion of the patient population. Market trends indicate growing recognition of the condition among healthcare providers, leading to improved diagnosis rates and earlier therapeutic intervention. The DelveInsight report further categorizes the pyoderma gangrenosum patient population based on disease severity, ulcer location, and associated comorbidities. This classification is essential for understanding treatment responses and developing targeted therapeutic strategies, as pyoderma gangrenosum often presents alongside inflammatory bowel disease, arthritis, and other autoimmune conditions. Discover evolving trends in the Pyoderma Gangrenosum patient pool forecasts @ Pyoderma Gangrenosum Epidemiology Analysis. Recent Developments In May 2025, InflaRx announced that the Independent Data Monitoring Committee (IDMC) recommended stopping their Phase 3 trial for vilobelimab in pyoderma gangrenosum due to futility. This recommendation was based on data analysis of the first 30 patients enrolled in the study. In April 2025, the FDA granted orphan drug designation to spesolimab-sbzo for the treatment of pyoderma gangrenosum. This designation provides incentives for developing treatments for rare diseases affecting fewer than 200,000 people in the United States. In January 2025, researchers reported successful treatment of PG complicated by myelofibrosis using a combination of systemic corticosteroid, adalimumab, and ruxolitinib. This represents an innovative approach for complex cases with comorbidities. Discover recent advancements in the Pyoderma Gangrenosum treatment landscape @ Pyoderma Gangrenosum Recent Developments. While there is no definitive cure for pyoderma gangrenosum, several treatment approaches focus on managing inflammation and promoting wound healing. Current therapeutic options include systemic corticosteroids, immunosuppressive agents, and topical treatments, though these approaches often provide limited efficacy and carry significant side effect burdens. The treatment landscape is evolving toward more targeted therapies that address the underlying inflammatory pathways responsible for tissue destruction. According to the DelveInsight report, the pyoderma gangrenosum therapies pipeline shows promising developments, with several novel treatments in late-stage clinical development. The pipeline focuses on therapeutics such as Vilobelimab (InflaRx) in Phase 3, Guselkumab (Janssen Scientific Affairs, LLC) in Phase 2, among others. Several companies are exploring innovative mechanisms of action to address the significant unmet medical needs in this rare disease area. Pyoderma gangrenosum pipeline development activities also include detailed analysis of collaborations, acquisitions, mergers, licensing agreements, and patent landscapes for emerging pyoderma gangrenosum therapies. The pyoderma gangrenosum treatment market is highly competitive, with major players including Johnson & Johnson, AbbVie, Amgen, Novartis, Eli Lilly and Company, Genentech, Galderma, Bristol Myers Squibb, Pfizer, LEO Pharma, and many others actively advancing therapies through robust research and development programs and strategic collaborations. These companies are leveraging their expertise in immunology and dermatology to develop targeted therapies for this challenging condition. Looking ahead, the pyoderma gangrenosum market is expected to witness continued innovation driven by rising disease awareness, incremental healthcare spending worldwide, and enhanced understanding of disease pathogenesis. The market expansion is anticipated to enable drug manufacturers to penetrate more effectively into this specialized therapeutic area. Companies and academic institutions are working collaboratively to assess challenges and identify opportunities that could influence pyoderma gangrenosum research and development activities. While significant progress is being made in understanding the immune system dysfunction underlying pyoderma gangrenosum, challenges remain in developing treatments that can achieve rapid ulcer healing, prevent disease recurrence, and improve overall quality of life for patients. Emerging therapeutic approaches focusing on novel immunomodulatory mechanisms, wound healing enhancement, and pain management hold promise for addressing these unmet needs and further transforming the treatment landscape. DelveInsight's analysis underscores that despite therapeutic advances, substantial opportunities remain for developing more effective, convenient, and accessible treatment options that can achieve durable remission and improved patient outcomes. The reimbursement landscape is also evolving to support innovative therapies for rare diseases, creating favorable market conditions for continued investment and development. As research continues and clinical understanding grows, the pyoderma gangrenosum market is poised for remarkable expansion and therapeutic innovation through 2032. Table of Contents 1. Key Insights 2. Executive Summary of Pyoderma Gangrenosum 3. Competitive Intelligence Analysis for Pyoderma Gangrenosum 4. Pyoderma Gangrenosum Market Overview at a Glance 5. Pyoderma Gangrenosum: Disease Background and Overview 6. Pyoderma Gangrenosum Patient Journey 7. Pyoderma Gangrenosum Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. Pyoderma Gangrenosum Unmet Needs 10. Key Endpoints of Pyoderma Gangrenosum Treatment 11. Pyoderma Gangrenosum Marketed Products 12. Pyoderma Gangrenosum Emerging Therapies 13. Pyoderma Gangrenosum: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Access and Reimbursement Overview of Pyoderma Gangrenosum 17. KOL Views 18. Pyoderma Gangrenosum Market Drivers 19. Pyoderma Gangrenosum Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight Related Reports Pyoderma Gangrenosum Pipeline Insight Pyoderma Gangrenosum pipeline insight provides comprehensive insights about the Pyoderma Gangrenosum pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Pyoderma Gangrenosum companies, including InflaRx GmbH, Janssen Scientific Affairs, LLC, and Boehringer Ingelheim, among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
CTV News
an hour ago
- CTV News
‘We've got you': School drives collecting supplies at Edmonton malls
The Pack the Pack initiative at Kingsway Mall aims to collect school supplies for Edmonton students. (CTV News Edmonton/Sean McClune) With back to school on the horizon, the cost of a child's school supplies list can be daunting for many families. But two initiatives are hoping to alleviate some of the pressure by collecting school supplies to be distributed to schools across the city. The Edmonton Public Schools Foundation (EPSF) has partnered with Kingsway Mall to 'pack the pack.' 'We are hoping to pack this backpack with new or unused school supplies in support of students this fall,' said EPSF acting director Catherine Bay. 'When students can start the year feeling prepared, they'll be a lot more confident in their learning.' A 'most needed' list of supplies is available on the EPSF website, and includes items like Duo-Tangs, notebooks, pencils, pencil crayons and binders. Bay said she's seen a need for supplies which has been growing every year. According to shopping lists from some Edmonton public schools, families with kids in elementary and junior high could be spending $50-$100 for a basic supply list. 'September tends to be a very expensive month for many families, and so the need just keeps increasing,' said Bay. 'Our goal is to be able to respond positively to students who do need that extra support. 'Don't worry, we've got you.' The drive is running until Sept. 6 at Kingsway Mall. SUPPLYDRIVE West Edmonton Mall is holding a school supplies drive until Aug. 17. (CTV News Edmonton/Sean McClune) But if you happen to be in the city's west end, West Edmonton Mall is also holding a drive in partnership with WEM Volkswagen and London Drugs to fill a bus with school supplies. Anna Alfonso, vice-president of marketing for West Edmonton Mall, said donations will be given to community partner Bent Arrow Traditional Healing Society and its family resource network. 'We are hoping for over 1,000 items donated,' said Alfonso. 'London Drugs has generously committed to providing backpacks and school supplies as well, and West Edmonton Mall is matching up to 100 items of school supplies donated.' SUPPLYDRIVE People can drop off new and unused school supplies at this Volkswagen van in West Edmonton Mall until Aug. 17. (CTV News Edmonton/Sean McClune) And while you might be picturing a big yellow school bus, the vehicle being filled is actually a Volkswagen bus that will be near Bourbon Street until Aug. 17. 'It's a fun play on what the city did with 'stuff a bus,'' said Alfonso. With files from CTV News Edmonton's Nahreman Issa
CBC
an hour ago
- CBC
Renovation at Puvirnituq's airport detours medevac flights
Inuulitsivik Health Centre in Puvirnituq, Que., serves seven communities in the region. Normally, the community's airstrip is big enough to land jets, but maintenace on the runway means it's been cut if in half. Now only small planes can land.
